Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves Watson Pharma chewable contraceptive
Watson Pharma claims that its contraceptive product is the first and only low dose oral contraceptive to combine 0.8mg norethindrone and 0.025mg ethinyl estradiol in chewable form, with
Watson Pharma claims that its contraceptive product is the first and only low dose oral contraceptive to combine 0.8mg norethindrone and 0.025mg ethinyl estradiol in chewable form, with
The new patent, US 7,847,066, describes the invention of a universal assay for UDP-glycosyltransferases based on direct detection of UDP in a high-throughput format. BellBrook Labs claims with
Ambrisentan is a non-sulfonamide, propanoic acid-class, endothelin receptor antagonist that is selective for the endothelin type-A (ETA) receptor. Gilead Sciences’ decision is based on the interim analysis of
Certriad is an investigational compound under joint development by AstraZeneca and Abbott for the treatment of mixed dyslipidemia. Abbott and AstraZeneca’s decision was made after careful consideration of
The funds will be designated and used by Oramed Ltd to support further R&D and clinical study of its Oral Insulin capsule and Oral GLP1-Analog. Oramed Pharmaceuticals CEO
In its CRL, the agency confirmed that patients with Coma Grade I/II observed a numerically higher rate of transplant-free survival, but also noted that there was not sufficient
ISIS-APOCIIIRx works by inhibiting the production of apolipoprotein C-III (apoC-III), a traditionally ‘undruggable’ target that plays an important role in the regulation of triglycerides. Isis Cardiovascular Diseases Drug
The FlexStent Biliary Self Expanding Stent System is indicated for the palliative treatment of biliary strictures resulting from malignant neoplasms. The expansion of the FlexStent Biliary Stent size
Naprod Life Sciences and Pharmasyntez will sign a memorandum of understanding for setting up a manufacturing unit in Saint Petersburg, Russia, with technology transfer by Naprod. Apart from
The French regulatory authority (AFSSAPS) has authorized manufacturing operations including the production of biotechnology products, immunology products and extracted products from animal or human origin. The new facility